Estrogen Inhibits Paclitaxel-Induced Apoptosis via the Phosphorylation of Apoptosis Signal-Regulating Kinase 1 in Human Ovarian Cancer Cell Lines

Endocrinology

Volumn 145, Issue 1, 2004, Pages 49-58

  Mabuchi, Seiji ^a   Ohmichi, Masahide ^a   Kimura, Akiko ^a   Nishio, Yukihiro ^a   Arimoto Ishida, Emi ^a   Yada Hashimoto, Namiko ^a   Tasaka, Keiichi ^a   Murata, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALANINE; ANTIESTROGEN; APOPTOSIS SIGNAL REGULATING KINASE 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; SERINE; STRESS ACTIVATED PROTEIN KINASE;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DAMAGE; CELL VIABILITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, PAPILLARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; ESTROGENS; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE KINASE 5; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; RECEPTORS, ESTROGEN; SERINE;

EID: 0347719531     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0792     Document Type: Article

References (60)

1. Rao BR, Slotman BJ 1996 Endocrine role in ovarian cancer. Endocr Relat Cancer 3:309-326
2. Weiss NS, Rossing MA 2001 Oestrogen-replacement therapy and risk on ovarian cancer. Lancet 358:438
3. Lacey Jr JV, Mink FJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C 2002 Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334-341
4. Guidozzi F, Daponte A 1999 Estrogen replacement therapy for ovarian carcinoma survivors. Cancer 86:1013-1018
5. Dickson RB, Lippman ME 1987 Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29-43
6. Lippman ME, Dickson RB 1989 Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Horm Res 45:383-435
7. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K 1997 Estrogen increases intracellular p26Bcl-2 tp p21 Bax ratios and inhibits taxolinduced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42:73-81
8. Teixeira C, Reed JC, Pratt MA 1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907
9. Razandi M, Pedram A, Levin ER 2000 Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 14:1434-1447
10. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6
11. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y 1997 Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90-94
12. Wang XS, Diene K, Jannuzzi D, Trollinger D, Tan TH, Lichenstein H, Zukowski M, Yao Z 1996 Molecular cloning and characterization of a novel protein kinase with a catalytic domain homologous to mitogen-activated protein kinase kinase kinase. J Biol Chem 271:31607-31611
13. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J 1998 Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 273:4928-4936
14. Chen Z, Seimiya H, Naito M, Mashima T, Kizaki A, Dan S, Imaizumi M, Ichijo H, Miyazono K, Tsuruo T 1999 ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene 18:173-180
15. Gotoh Y, Cooper JA 1998 Reactive oxygen species- and dimerization- induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-α signal transduction. J Biol Chem 273:17477-17482
16. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ 2001 Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor a (ERα) via interaction between ERα and PI3K. Cancer Res 61:5985-5991
17. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK 2000 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541
18. Franke TF, Kaplan DR, Cantley LC 1997 PI3K: downstream AKTion blocks apoptosis. Cell 88:435-437
19. Zhang L, Rubinow DR, Xaing G, Li BS, Chang YH, Maric D, Barker JL, Ma W 2001 Estrogen protects against â-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. Neuroreport 12:1919-1923
20. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KD, Schaefer E, Kajstura J, Anversa P, Sussman MA 2001 Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 88:1020-1027
21. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ 2003 AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278:23432-23440
22. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV 2001 Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 21:893-901
23. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20:6050-6059
24. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF 1985 Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583-2586
25. Toyoshima F, Moriguchi T, Nishida E 1997 Fas induces cytoplasmic apoptotic responses and activation of the MKK7-JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J Cell Biol 139:1005-1015
26. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M, Chambon P 1986 Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 24:77-83
27. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y 1999 Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274:31648-31654
28. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y 2000 Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60:5988-5994
29. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y 2002 Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277:33490-33500
30. Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanada Y, Jikihara H, Matsuura N, Murata Y 1999 The role of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) cascade in gonadotropin-releasing hormone induced growth inhibition of human ovarian cancer cell line. Cancer Res 59:5133-5142
31. Jones J, Lagasse LD, Karlan BY 1994 Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Gynecol Oncol 55:421-426.
32. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattorossi A, Isola G, Benedetti Panici P, Mancuso S 1999 Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 79:257-263
33. Zimmermann, S, Moelling K 1999 Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741-1744
34. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241
35. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW 1997 Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation 95:1505-1514
36. Razandi M, Pedram A, Levin ER 2000 Estrogen signals to the preservation of endothelial cell form and function. J Biol Chem 275:38540-38546
37. Sudoh N, Toba K, Akishita M, Ako J, Hashimoto M, Iijima K, Kim S, Liang YQ, Ohike Y, Watanabe T, Yamazaki I, Yoshizumi M, Eto M, Ouchi Y 2001 Estrogen prevents oxidative stress-induced endothelial cell apoptosis in rats. Circulation 103:724-729
38. Blobel GA, Orkin SH 1996 Estrogen-induced apoptosis by inhibition of the erythroid transcription factor GATA-1. Mol Cell Biol 16:1687-1694
39. Ahmad S, Singh N, Glazer RI 1999 Role of AKT1 in 17â-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol 58:425-430
40. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W 2002 The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80:239-256
41. Mori A, Tsutsumi S, Takahashi K, Toya M, Yoshida M, Du B, Kawagoe J, Nakahara K, Ohmichi M, Kurachi H 2003 Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 178:417-426
42. Aronica SM, Kraus WL, Katzenellenbogen BS 1994 Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 91:8517-8521
43. Tesarik J, Mendoza C 1995 Nongenomic effects of 17 â-estradiol on maturing human oocytes: relationship to oocyte developmental potential. J Clin Endocrinol Metab 80:1438-1443
44. Le Mellay V, Grosse B, Lieberherr M 1997 Phospholipase Cβ and membrane action of calcitriol and estradiol. J Biol Chem 272:11902-11907
45. Mendelsohn ME, Karas RH 1999 The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811
46. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, Murata Y 2001 Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 276:3459-3467
47. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC 2001 Estradiol upregulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 142:2351-2360
48. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T 1998 Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367-5373
49. Lau KM, Mok SC, Ho SM 1999 Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96:5722-5727
50. Norfleet AM, Clarke CH, Gametchu B, Watson CS 2000 Antibodies to the estrogen receptor-α modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. FASEB J 14:157-165
51. Marquez DC, Pietras RJ 2001 Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20: 5420-5430
52. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F 2000 Identification of a new isoform of the human estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J 19:4688-4700
53. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H, Wimalasena J 1999 Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways ovarian cancer cells. J Biol Chem 274:8208-8216
54. Blagosklonny MV, Schulte TW, Ngyuen P, Mimnaugh EG, Trepel J, Neckers L 1995 Taxol induction of p21WAF1 and p53 requires c-raf-1 Cancer Res 55:4623-4626
55. Blagosklonny MV, Schulte TW, Nguyen P, Trepel J, Neckers LM 1996 Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56:1851-1854
56. Huang Y, Sheikh MS, Fornace Jr AJ, Holbrook NJ 1999 Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene 18:3431-3439
57. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868
58. Warenius HM, Seabra LA, Maw P 1996 Sensitivity to cis-diaminedichloro- platinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int J Cancer 67:224-231
59. Clark AS, West K, Streicher S, Dennis PA 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1:707-717
60. Perez-Tenorio G, Stal O 2002 Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545